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The implementation of universal health coverage scheme in Thailand allows quality, equitable and
accessible health care for all. Patients with life threatening and chronic diseases can get access to bio-
therapeutic products to treat their ailments. This triggered a major impact on the need for speciﬁc
guidelines in evaluation of similar biotherapeutic products in order to standardize the regulatory
pathway to license this class of products ensuring that the products meet acceptable levels of quality,
safety and efﬁcacy. The development of similar biotherapeutic products (SBP) should be considered to
ensure therapeutic equivalence of biotherapeutics products at more affordable prices. This will lead to
greater ease and speed of approval and assurance of the quality, safety and efﬁcacy of these products.
Therefore, we report herein the SBP situation in Thailand.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
Thailand is one of many developing countries with a universal
health coverage scheme whereby many biotherapeutic products
have been recognized and tender public purchased by the National
Health Security Ofﬁce in order to treat life threatening and chronic
diseases e.g. EPO, interferon and monoclonal antibody. The inno-
vator and original biotherapeutic products are very costly thereby
limiting their access to patients, leading to the acceptability of
those biotherapeutic products, which have been subsequently
licensed to original products by Thai Food and Drug Administration
(TFDA) because of their affordable prices.2. Legislative basis for biotherapeutic products
By deﬁnition biotherapeutic products are classiﬁed as drugs and
havebeen regulatedunder legal frameworkofDrugActB.E2510 (A.D.
1967) therefore the same regulations pertaining to drugs shall apply.
However there is someminor differencewith respect to clinical data
requirements. For biotherapeutics, clinical efﬁcacy should be proved
whereas bioequivalence is required for generic drugs.þ66 2591 8463.
aphollert), kriangtungsanga@
ll rights reserved. The World HealthAccording to the provision of the Drug Act, no renewal of
marketing authorization is required as its validity is warranted
throughout the entire lifetime of the authorized licensee. Never-
theless, the marketing authorization shall be automatically with-
drawn if neither importation nor production of two consecutive
years is met.3. Approach for similar biotherapeutic products
With advancement in biotechnological sciences, there has been
a rapid expansion in developing and manufacturing of bio-
therapeutic products. This is especially true with respect to similar
biological products.
At present TFDA has no speciﬁc guidelines in evaluating similar
biotherapeutic products by which there is a need to justify the
therapeutic equivalence between the innovatives with biosimilar
products.
Therefore, TFDA has established a technical subcommittee
called “Subcommittee on Biosimilar Products” to review current
situations and existing regulations in order to develop such
guidelines based on WHO’s guideline on evaluation of similar
biotherapeutic products (SBP). The objective is to strengthen the
evaluation and assurance of quality, safety and efﬁcacy of similar
biotherapeutic products thus increasing the credibility of thera-
peutic equivalence of biotherapeutic products among health care
professionals.Organization has granted the Publisher permission for the reproduction of this article.
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“Similar Biotherapeutic Product (SBP)” and “Reference Bio-
therapeutic Product (RBP)” should be discussed and agreed by this
subcommittee.
4. Product licensed and under existing process
TFDA has licensed the original biotherapeutic products based on
evaluation of full dossiers on quality, non-clinical and clinical data.
Those biotherapeutic products which have been subsequently
licensed as biogeneric products were evaluated based on stand
alone approach. This abbreviated stand alone approach-only
requires full quality dossier and reduced clinical data based on non-
comparative exercises.
5. Addressed issues
For those existing biotherapeutic products which have previ-
ously been approved and subsequently licensed for marketing in
Thailand prior to full implementation of new regulation, they are
subject to the re-evaluation process in order to be standardized
under comparability exercises. However, it may take a few more
years before TFDA is able to embark on a re-evaluation process for
these biogeneric products as subsequently licensed biotherapeutic
products. The new regulatory pathway for reviewing existing bio-
therapeutic products shall be based on the re-evaluation processes
as follows:
1) The Quality aspect shall be based on the latest version of
National or International Compendia or other relevant Inter-
national Guidelines.
2) The Clinical aspect shall be based on clinical data of each
therapeutic indication. Extrapolation of indication shall not be
allowed unless being approved and justiﬁed by TFDA’s invited
experts.
3) The Safety aspect shall be based on Post-Marketing Surveil-
lance and/or Periodic Safety Update Report.
- New drugs: Full quality, safety and efﬁcacy dossier- Biogeneric: Quality plus reduced clinical dossier with non-
comparative manner (Section 4). This product class would
be converted to subsequently licensed biotherapeutic prod-
ucts after re-evaluation project will be completed.
- Existing biotherapeutics (or subsequently licensed bio-
therapeutic products): Subject to re-evaluation (Section 5)
- Similar biotherapeutical products: Comparative quality,
reduced non-clinical and clinical dossier in comparative
manner (similar to WHO guidelines)6. Differences of Thai SBP guideline from WHO guidelines
We expect to use WHO guidelines as a basis for establishing
regulatory frameworks for licensing of the similar biotherapeutic
products as we aim to provide acceptable principles for licensing
biotherapeutic products that are claimed to be similar to original
biotherapeutic products of assured quality, safety, and efﬁcacy, that
have been licensed based on a full licensing dossier. On the basis of
proven similarity, the licensing of a SBP will rely on full similar
quality with head-to-head comparison and in part on non-clinical
and clinical data generated with an already licensed reference bio-
therapeutic product (RBP), which is licensed in Thailand in principle.
7. Plan to implement SBP guideline
It is expected that in the near future within the year 2011, TFDA
will be able to develop its own regulations based on the WHO’s
guideline on evaluation of SBP. This new Regulation on SBP will be
fully implemented by not only the National Regulatory Authority
but also industries.
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